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Abstract
Background: Rats fed a high-fat and high-sucrose (HF) diet develop hepatic steatosis and hyperlipidemia. There
are several reports that a change in nutritional status affects hepatic levels of drug-metabolizing enzymes. Synthetic
inulin is a dietary component that completely evades glucide digestion. Supplementing a HF diet with inulin
ameliorates hypertriglycemia and hepatic steatosis, but not hypercholesterolemia. This study aimed at
distinguishing the effects of synthetic inulin and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
(statin), which inhibit cholesterol biosynthesis.
Methods: We examined effects of co-treatment with synthetic inulin (5%) and fluvastatin (0, 4, and 8 mg/kg, per
os) on body weight, epidydimal white adipose tissue weight, serum and hepatic lipid profiles, and hepatic
cytochrome P450 (CYP) mRNA and protein profiles in rats fed a standard diet or a HF diet for 3 weeks.
Results: Treatment with the synthetic inulin (5%) or fluvastatin at 4 mg/kg (lethal dose in rats fed the HF diet, 8
mg/kg) ameliorated the elevation in hepatic triacylglycerol and total cholesterol levels in rats fed the HF diet.
Whereas co-treatment with the inulin (5%) and fluvastatin (4 mg/kg) had a tendency to more strongly suppress
the elevation in serum levels of very low density lipoprotein triacylglycerol than either treatment alone, no
additive or synergistic effect was found in decrease in hepatic lipid levels. Hepatic levels of CYP1A1/2 and
CYP2E1 mRNA and protein and methoxyresorufin O-demethylase and ethoxyresorufin O-deethylase activities
were reduced in rats fed the HF diet. The synthetic inulin alleviated the reduction in hepatic levels of CYP1A1/2
and CYP2E1 mRNA and protein more strongly than fluvastatin, and no synergistic effects were observed on co-
treatment. Furthermore, hepatic levels of aryl hydrocarbon receptor mRNA were decreased in rats fed the HF
diet and recovered to near normal values with the intake of dietary inulin, which correlated with change in
CYP1A1/2.
Conclusions: Dietary inulin alone was effective to prevent the development of hepatic steatosis, ameliorate
nutritional effects, and alleviate the hepatic change in the expression of CYP1A1/2 and CYP2E1, while co-treatment
with statin did not have additive or synergistic effects and statin may cause adverse effects in rats fed the HF diet.
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The liver plays a central role in metabolizing therapeutic
drugs and environmental contaminants. The activities of
drug-metabolizing phase I and II enzymes in the body are
affected by the genotypes of the translating gene and also
by non-genetic factors including environmental factors.
The expression of cytochrome P450 (CYP) 2E1, a micro-
somal oxidase involved with fatty acid ω-oxidation, as well
as CYP4A, is upregulated during starvation, fasting, obe-
sity and hyperlipidemia [1-4]. Elevated levels of CYP2E1
have been largely attributed to the pathogenesis of liver
disease in patients with nonalcoholic steatohepatitis
(NASH) [3-7]. In contrast, Fisher et al. [8] reported that
the expression of CYP2E1 significantly decreased with the
progression of human nonalcoholic fatty liver disease
(NAFLD) from simple fatty liver (steatosis) to the more
severe NASH, and the expression of CYP1A2, CYP2C19,
CYP2B6 and CYP3A4 also tended to decrease with
increasing severity of NAFLD. These observations were
not consistent with reports of increased CYP2E1 expres-
sion in livers from patients with NAFLD [9,10]. Although
nutritional factors such as starvation, fasting and a high-
lipid diet have been reported to modulate liver microsomal
CYP composition, leading to the altered hepatic metabo-
lism of drugs, carcinogens, steroid hormones, and fatty
acids, little is known about whether the suppression of
lipid accumulation in fatty liver alleviates the changes in
hepatic CYP composition. Thus, it is worth investigating
how to suppress the changes in hepatic CYP composition
associated with hepatic steatosis, which is proposed to be
the setting for more severe liver diseases such as nonalco-
holic steatohepatitis with histologic signs of fibrosis and
necroinflammation through to cirrhosis, terminal liver fail-
ure and hepatocellular carcinoma [11].
Some dietary components that completely evade diges-
tion, such as resistant starch and inulin, have been demon-
strated to exert systemic effects by modifying lipid
metabolism [12-14]. Previously [15], we reported Bacillus
sp. 217 C-1 expressing a highly efficient enzyme that con-
verts sucrose into inulin molecules, which comprise a lin-
ear polymer linked by b(2 - 1) glycoside bridges of D-
fructose with one terminal glucose similar to plant-derived
inulin and have a similar property for in vitro fermentation
to plant-derived inulin and suppress the growth of harmful
bacteria more strongly than fructooligosaccharide [14-17].
Feeding a high-fat and high-sucrose (HF) diet to rats for 8
to 12 weeks produced hyperlipidemia and hepatic steato-
sis, and supplementing the diet with the synthetic inulin
reduced the elevation in body weight, epidydimal white
adipose tissue (WAT) weight, and serum and hepatic
levels of triacylglycerols [15,18]. Thus, in this study, we
characterized the changes in expression of CYP mRNA
and protein associated with alterations in nutritional status
such as serum and hepatic lipid profiles. Statin, 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase inhi-
bitor, whose competitive inhibition of HMG-CoA reduc-
tase reduces the amount of HMG-CoA converted to
mevalonate, the rate-limiting step of cholesterol biosynth-
esis, is a member of an important class of lipid-lowering
drugs. Since the synthetic inulin did not suppress the ele-
vation in serum cholesterol levels of rats fed a HF diet, we
investigated the influence of co-treatment with the syn-
thetic inulin and fluvastatin on the health of rats fed a HF
diet and the changes in hepatic CYP expression caused by
fatty liver.
Methods
Chemicals
Inulin [average degree of fructose polymerization (DP) =
16 ~ 17] enzymatically synthesized from sucrose by an
inulin-producing enzyme was prepared as reported pre-
viously [15]. Fluvastatin was purchased from Toronto
Research Chemicals, Inc. (North Yolk, Canada).
Experimental animals
All experiments followed protocols approved by the
Institutional Animal Care and Life Committee, University
of Shizuoka. Male Wistar rats were obtained from Japan
Charles River (Tokyo, Japan) at 6 weeks of age. Animals
were acclimatized for one week prior to the experiment,
housed in stainless-steel hanging cages with free access
to food and water, and maintained on a 12-h light-dark
cycle. All animals were randomly assigned to the stan-
dard (SD) diet, 5% inulin-supplemented standard (SD +
I) diet, high-fat and high-sucrose (HF) diet, or 5% inulin-
supplemented high-fat and high-sucrose (HF + I) diet
[17-19]. After one week on either diet, each group was
divided into three subgroups and given 0, 4, or 8 mg flu-
vastatin/kg/day (per os) (4 rats/group) since the lethal
dose of fluvastatin in SD diet- and HF diet-fed male rats
was 16 mg/kg/day and 8 mg/kg/day, respectively, with
the diet for 2 weeks [20]. The HF diet consisted of 19.7%
casein, 1% soybean oil, 10% lard, 4% mineral mixture, 1%
vitamin mixture, 0.15% choline chloride, 0.5% choles-
terol, 0.25% sodium cholate, 3.4% cellulose and 60%
sucrose (23.9% lipid, 56.8% carbohydrate and 19.3% pro-
tein [kJ]). The SD diet consisted of 23.8% crude protein,
5.1% crude fat, 3.2% crude fiber, 6.1% ash, 54% nitrogen-
free extract and 7.8% humidity (12.9% lipid, 60.4% carbo-
hydrate and 26.7% protein [kJ]). The rats were weighed
three times per week, and food intake in grams was mon-
itored. Each experiment was done at least twice.
Blood and tissue sampling
Rats about 4 h after removal of the diets unless other-
wise stated were anesthetized with diethyl ether, the
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drawn from the abdominal vena cava or portal vein into
syringes between 11:00 AM and 12:00 PM. To prepare
fasting animals, at the end of experimental period, the
groups were starved for 16 h before being sacrificed.
Plasma samples were separated from blood collected
into heparinized tubes by centrifugation, and serum
samples were separated from blood by centrifugation
after standing for 30 min at room temperature. The
resulting plasma/serum was stored at -80°C prior to
analysis. Livers were rapidly excised and weighed. The
liver median lobe was excised for the preparation of
microsomes, plasma membranes and nuclear extracts
and the extraction of RNA.
Biochemical analyses
Blood and tissue sampling was done as described pre-
viously [19]. Portal plasma glucose concentrations were
determined by the hexokinase method using commercial
reagents (R-Biopharm AG, Darmstadt, Germany). Fro-
zen livers (about 0.5 g) were homogenized in 20
volumes (the SD group) or 100 volumes (the HF group)
of 0.9% NaCl containing 0.1% Triton X-100, and triacyl-
glycerol and total cholesterol concentrations in serum
and liver were estimated with kits from Shino Test
(Tokyo, Japan).
Triacylglycerol and total cholesterol levels in serum
lipoproteins were determined by a dual detection HPLC
system with two tandemly connected TSKgel Lipopro-
pak XL columns (300 × 7.8 mm; TOSOH) in Skylight
Biotech Inc. (Akita, Japan) [17].
Preparation of microsomes
Liver microsomes were prepared by differential centrifu-
gation, first at 9,000 g for 15 min then at 105,000 g for
60 min, at 4°C and stored at -80°C. The microsomal
protein concentration was determined with a bicincho-
ninic acid protein assay kit (Pierce Chemical, Rockford,
IL) using bovine serum albumin as a standard.
Immunoblot analysis
Microsomal proteins (20 μg) were resolved on a sodium
dodecyl sulfate-12.5% polyacrylamide gel, and electro-
blotted onto a polyvinylidene difluoride membrane
(Millipore Corporation, Bedford MA). The immunoblots
were incubated with primary antibodies against rat
C Y P 1 A 1( t h ea n t i b o d ya l s or e c o g n i z e sr a tC Y P 1 A 2 ,
whose molecular weight is lower than that of rat
CYP1A1) (dilution 1:10,000), rat CYP2B1 (dilution
1:10,000), rat CYP2C11 (dilution 1:10,000), rat CYP2E1
(dilution 1:5,000), rat CYP3A2 (dilution 1:10,000), rat
CYP4A1 (dilution 1:10,000), and rat NADPH P450
reductase (CPR) (dilution 1:10,000) (Daiichi Pure Che-
micals Co., Tokyo, Japan). Antigen-antibody complexes
were detected using the appropriate secondary antibody
conjugated with horseradish peroxidase and visualized
with an enhanced chemiluminescence system (GE
Healthcare Bio-Sciences, Piscataway, NJ).
Determination of mRNA levels
Total RNA was prepared from the liver using TRIZOL
reagent (Invitrogen Life Technologies, Carlsbad, CA).
Samples were quantified by spectrophotometry, and 1
μg of total RNA was used to generate cDNA by reverse
transcription (RT) with a Prime Script RT reagent kit
(TaKaRa Bio. Inc., Otsu, Japan) according to the manu-
facturer’s directions. cDNA synthesized from 50 ng of
total RNA was subjected to a quantitative real-time
polymerase chain reaction (PCR) as described previously
[18] with an ABI PRISM 7000 Sequence Detector
(Applied Biosystems, Foster City, CA) using Premix Ex
Taq reagent (TaKaRa Bio Inc.) for the TaqMan probe-
based method or SYBR Premix Ex Taq reagent (TaKaRa
Bio Inc.) for the intercalation reaction with SYBR Green
I according to the manufacturer’s specifications. The
TaqMan probes and primers for rat fatty acid synthase
(FAS, NM_017332) and rat b-actin (NM_031144), rat
carnitine palmitoyltransferase 1a (CPT1a, NM_031559)
[17], rat aryl hydrocarbon receptor (AhR, NM_013149)
[21], rat CYP1A1 (NM_012540), rat CYP1A2
(NM_012541), rat CYP2B1 (NM_001134844), rat
CYP3A1 (NM_173144), and rat CYP3A2 (NM_153312),
rat CYP2C11 (NM_019184), rat CYP4A1 (NM_175837),
rat CYP4A2 (NM_001044770), rat CYP4A3
(NM_175760), rat CPR (NM_031576), rat constitutive
androstane receptor (CAR, NM_022941), rat pregnane
X receptor (PXR, NM_052980), and rat retinoid X
receptor (RXR, NM_012805) [19], were as reported pre-
viously, and those for rat CYP2E1 (NM_031543) (assay
identification number Rn00580624_ml) and rat b-actin
(Rn00667869_ml) were assay-on-demand gene expres-
sion products (Applied Biosystems). The primers for rat
aryl hydrocarbon nuclear translocator (ARNT,
NM_012780) were 5’-GCACCCAGATGATGTGGATA-
3’ (forward) and 5’-ATTCCTGCATCTGTTCCTCAA-3’
(reverse). The thermal profiles was as follows: 10 sec at
95°C, then a two-step PCR for 40 cycles of 95°C for 5
sec followed by 60°C for 30 sec. b-Actin was used to
normalize gene expression in all samples. Fold-increase
values were calculated by subtracting the mean differ-
ence of gene and b-actin cycle threshold Ct numbers for
each treatment group from the mean difference for the
vehicle-treated group and raising the difference to the
power of 2 (2
-ΔΔCt).
Resorufin assay
The activities of ethoxyresorufin O-deethylase [reported
to prefer CYP1A1 [22]] and methoxyresorufin O-
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measured fluorometrically by the production of resoru-
fin using a Wallac 1420 ARVO plate reader (PerkinEl-
mer Inc., Wellesley, MA) with excitation and emission
wavelengths of 550 nm and 590 nm, respectively. The
incubation mixtures contained Tris-HCl (100 mM, pH
7.4), MgCl2 (3.3 mM), EDTA (1 mM), glucose-6-phos-
phate (3.3 mM), NADP (1.3 mM), glucose-6-phosphate
dehydrogenase (0.4 U/ml), ethoxyresorufin or methoxyr-
esorufin (5 μM) and microsomal protein (10 μg/ml).
NADPH was produced using the GENTEST NADPH
regenerating system (BD Biosciences, Woburn, MA).
The mixtures were incubated for 10 min at 37°C. The
rate at which resorufin was produced was determined
by comparison to the fluorescence of known amounts of
resorufin.
Statistics
Values are expressed as means ± standard errors. The
data were analyzed by ANOVA unless stated otherwise.
Fisher’s Protected Least Significant Difference test was
used to determine the significance of differences among
the groups. The level of statistical significance was set at
p < 0.05.
Results
Effects of co-treatment with dietary inulin and fluvastatin
on biomarkers of metabolic disease in rats fed the HF
diet
Rats fed the HF diet for 3 weeks showed fatty livers,
which were not associated with an increase in serum
aspartate aminotransferase, alanine aminotransferase,
and g-glutamyl transpeptidase levels (data not shown),
in addition to an increase in serum triacylglycerol and
total cholesterol levels, portal plasma insulin levels, and
epididymal WAT and liver weights (Figures 1, 2, 3).
Body weight (345.4 ± 7.2 g) and epididymal WAT
weight (4.21 ± 0.42 g) of the HF group had a tendency
to increase compared to those of the SD group (336.3 ±
7.0 g and 3.72 ± 0.16 g, respectively) and liver weight of
the HF group (19.6 ± 1.1 g) significantly increased com-
p a r e dt ot h a to ft h eS Dg r o u p( 1 3 . 4±0 . 4g )( F i g u r e1 ) ,
while the food intake of the HF group (20.6 ± 0.4 g/day)
tended to be lower than that of the SD group (22.0 ±
0 . 7g / d a y ) .T h ef a c tt h a tt h e r ew e r en os i g n i f i c a n tr i s e s
in body weight of animals fed a high-sugar and high-fat
diet has been reported also in monkeys [23]. Consump-
tion of the synthetic inulin for 3 weeks in the HF group
suppressed the increase in the weights of the epididymal
WAT and liver, hepatic levels of triacylglycerol and cho-
lesterol, serum lipoprotein triacylglycerol levels, espe-
cially very low density lipoprotein (VLDL) triacylglycerol
levels, and portal plasma insulin levels, but not serum
total cholesterol levels (Figures 1, 2, 3). In addition, the
intake of dietary inulin reduced portal glucose levels in
rats fed not only the HF diet but also the SD diet (Fig-
ure 1C). Effect of synthetic inulin on portal plasma glu-
cose levels in the fasting HF rats were similar as that in
the non-fasting HF rats (Figure 3). Furthermore, the
increase in serum VLDL triacylglycerol levels in the HF
group and its suppression by the intake of synthetic inu-
lin were found in the fasting rats as well as in the non-
fasting rats (Figure 3). The portal plasma glucose levels
in the non-fasting HF group were almost the same as
those in the non-fasting SD group (Figure 1). The obser-
vation may result from the fact that the portal plasma
insulin levels in the HF group markedly increased com-
pared to those in the SD group (Figure 3C). Since rats
fed the HF diet and treated with fluvastatin at 8 mg/kg/
day died within 2 weeks [20], we examined the effect of
fluvastatin at 4 mg/kg/day (per os). Fluvastatin given at
4 mg/kg/day for 2 weeks, as a component of the diet,
also suppressed serum triacylglycerol levels and hepatic
triacylglycerol and total cholesterol levels, but not serum
total cholesterol levels, in rats fed the HF diet (Figures 1
and 2). As sown in Figure 1, the extent of the reduction
in epididymal WAT weights by fluvastatin was less than
that by synthetic inulin at the concentration of 5%,
which has been reported to suppress the development
of fatty liver [15]. Unexpectedly, co-treatment with inu-
lin and fluvastatin (4 mg/kg) slightly reduced body
weights and had a tendency to synergistically or addi-
tively suppress the change in epididymal WAT weights
and serum triacylglycerol levels (Figures 1 and 2).
Next, to investigate the mechanism behind the anti-
hyperlipidemic effects of dietary inulin, we examined
effects on the hepatic gene expression of enzymes such
as fatty acid synthase (FAS) and carnitine palmitoyl-
transferase Ia (CPT1a), involved in the synthesis of fatty
acid and b-oxidation, respectively. Consistent with the
increase in serum and hepatic triacylglycerol levels, rats
fed the HF diet for 3 weeks showed a significant eleva-
tion in hepatic FAS mRNA levels and a significant
decrease in CPT1a mRNA levels (Figure 4). Dietary inu-
lin had a tendency to suppress the up-regulation of FAS
mRNA expression in rats fed the HF diet and sup-
pressed the down-regulation of CPT1a mRNA expres-
sion, while fluvastatin had a tendency to suppress both.
The co-treatment was not additive or synergistic (Figure
4).
Nutritional status affects the hepatic expression of drug-
metabolizing phase I enzymes in rats
Consumption of the HF diet for 3 weeks resulted in a
significant decrease in hepatic CYP1A1, CYP1A2, and
CYP2E1 mRNA levels to 10 ± 2%, 22 ± 2%, and 37 ±
7%, respectively, of the control values (Table 1). Pre-
viously [17], we reported that the administration of
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high cholesterol and triacylglycerol levels in blood, (300
mg/kg, i.p.) for 5 days reduced the hepatic protein level
of CYP1A2 to 20% of the control value and increased
the protein levels of CYP4As 4.1-fold. Thus, in this
study, we investigated the effect of co-treatment with
the synthetic inulin and fluvastatin on changes in the
expression of hepatic drug-metabolizing phase I
enzymes in rats fed the HF diet. Since fasting alters
hepatic expression of the enzymes such as CYP2E1, we
f o c u s e do na l t e r a t i o ni nt h ee x p r e s s i o no fh e p a t i cd r u g -
metabolizing phase I enzymes in non-fasting rats. As
shown in Table 1 and Figures 5 and 6, fluvastatin at 4
mg/kg increased hepatic CYP 1A1 and CYP1A2 mRNA
Figure 1 Effects of synthetic inulin and fluvastatin on body and tissue weights, portal glucose levels, and hepatic lipid profiles in rats
fed a standard (SD), inulin-supplemented standard (SD + I), high-fat and high-sucrose (HF), or inulin-supplemented high-fat and high-
sucrose (HF + I) diet. Rats (7 weeks of age) were fed the SD, SD + I, HF, or HF + I diet for 1 week, and then administered fluvastatin (0, 4, or 8
mg/kg) with the diet daily. The rats were sacrificed 14 days after starting the administration of fluvastatin. Values are the mean ± S.E. of 4
determinations. *p < 0.05, **p < 0.01, ***p < 0.001 versus SD diet-fed control rats; # p < 0.05, ##p < 0.01, ###p < 0.001 versus HF diet-fed control
rats. C, vehicle; F, fluvastatin; 4, 4 mg/kg; 8, 8 mg/kg.
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standard (SD), inulin-suplemented standard (SD + I), high-fat and high-sucrose (HF), or inulin-supplemented high-fat and high-sucrose
(HF + I) diet. Rats (7 weeks of age) were fed the SD, SD + I, HF, or HF + I diet for 1 week, and then administered fluvastatin (0 or 4 mg/kg) with
the diet daily. The rats were sacrificed 14 days after starting the administration of fluvastatin. Values are the mean ± S.E. of 4 determinations. *p
< 0.05, **p < 0.01, ***p < 0.001 versus SD diet-fed control rats; # p < 0.05, ##p < 0.01, ###p < 0.001 versus HF diet-fed control rats.
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plasma glucose levels in rats fed the SD, SD + I, HF, or HF + I diet. Rats (7 weeks of age) were fed each diet for 3 weeks. The rats were
sacrificed about 4 h after removal of the diet (non-fasting) or after starvation for 16 h. Values are the mean ± S.E. of 4 determinations. *p < 0.05,
***p < 0.001 versus SD diet-fed control rats; # p < 0.05, ###p < 0.001 versus HF diet-fed control rats. Open bar, non-fasting animals; closed bar,
fasting animals.
Figure 4 Liver gene expression [FAS mRNA (A) and CPT1a mRNA (B)] in rats in response to 3-week SD, SD + I, HF, or HF + I diets with
or without fluvastatin (0, 4 or 8 mg/kg/day). Rats (7 weeks of age) were fed the SD, SD + I, HF, or HF + I diet for 1 week, and then
administered fluvastatin (0, 4, or 8 mg/kg) with the diet daily. The rats were sacrificed 14 days after starting the administration of fluvastatin.
Values are the mean ± S.E. of 4 determinations. Fold-increase is expressed by taking the control values obtained from SD-fed animals as 1.0. *p <
0.05, **p < 0.01, ***p < 0.001 versus SD diet-fed control rats; # p < 0.05, ##p < 0.01, ###p < 0.001 versus HF diet-fed control rats.
Sugatani et al. Nutrition & Metabolism 2012, 9:23
http://www.nutritionandmetabolism.com/content/9/1/23
Page 7 of 14and protein levels in rats fed the SD diet, and slightly
restored them in rats fed the HF diet. Dietary inulin
recovered the reduced hepatic CYP1A1, CYP1A2, and
CYP2E1 mRNA and protein levels and ethoxyresorufin
O-deethylase and methoxyresorufin O-demethylase
activities in rats fed the HF diet to near the control
values, at the extent of the recovery being higher than
with fluvastatin (Table 1 and Figures 5, 6 and 7).
However, co-treatment with dietary inulin and fluvasta-
tin did not provide synergistic or additive effects on the
recovery of hepatic CYP1A1, CYP1A2, and CYP2E1
mRNA and protein levels and the CYP1A enzyme activ-
ities in rats fed the HF diet. Furthermore, we examined
effects of nutritional status on transcription factor
expression. As shown in Table 1, aryl hydrocarbon
receptor (AhR) and aryl hydrocarbon nuclear
Table 1 Liver gene expression in rats in response to each diet with or without fluvastatin
Gene SD (fold induction) Inulin-supplemented SD (fold
induction)
HF (fold induction) Inulin-supplemented HF (fold
induction)
Control Fluvastatin Control Fluvastatin Control Fluvastatin Control Fluvastatin
CYP1A1 1.00 ± 0.44 4.31 ± 0.03** 0.86 ± 0.24 3.13 ± 0.99* 0.10 ± 0.02*** 0.24 ± 0.12*** 0.31 ± 0.12*** 0.15 ± 0.06***
CYP1A2 1.00 ± 0.08 1.29 ± 0.06* 1.06 ± 0.09 1.34 ± 0.06* 0.22 ± 0.02*** 0.31 ± 0.02*** 0.52 ± 0.06***,
# 0.57 ± 0.03**,
#
CYP2B1 1.00 ± 0.28 1.43 ± 0.39 0.89 ± 0.20 0.83 ± 0.03 0.59 ± 0.09 0.68 ± 0.09 0.57 ± 0.15 0.23 ± 0.05*
CYP2C11 1.00 ± 0.04 0.82 ± 0.04 0.81 ± 0.15 0.85 ± 0.08 0.83 ± 0.05 0.76 ± 0.09 0.62 ± 0.15* 0.58 ± 0.03*
CYP2E1 1.00 ± 0.06 1.35 ± 0.12 1.43 ± 0.15** 1.47 ± 0.11* 0.37 ± 0.07** 0.84 ± 0.14
# 0.89 ± 0.10
# 0.44 ± 0.04*
CYP3A1 1.00 ± 0.09 0.81 ± 0.13 1.06 ± 0.05 0.88 ± 0.08 0.77 ± 0.11 0.91 ± 0.19 0.82 ± 0.07 0.54 ± 0.04*
CYP3A2 1.00 ± 0.09 0.81 ± 0.07 1.20 ± 0.10 0.87 ± 0.07 0.72 ± 0.09 0.78 ± 0.15 0.74 ± 0.05 0.68 ± 0.07*
CYP4A1 1.00 ± 0.06 1.28 ± 0.13 1.76 ± 0.73 1.20 ± 0.10 0.53 ± 0.04 0.64 ± 0.20 1.43 ± 0.28
# 1.12 ± 0.17
CYP4A2 1.00 ± 0.14 2.45 ± 0.54* 2.94 ± 0.54* 1.46 ± 0.19 0.42 ± 0.28 0.39 ± 0.27 1.00 ± 0.24 0.34 ± 0.01
CYP4A3 1.00 ± 0.08 1.08 ± 0.14 1.24 ± 0.40 0.80 ± 0.08 0.53 ± 0.03 0.55 ± 0.13 1.33 ± 0.29 1.01 ± 0.08
CPR 1.00 ± 0.09 1.17 ± 0.13 1.17 ± 0.07 1.45 ± 0.12 1.20 ± 0.12 1.03 ± 0.05 1.23 ± 0.15 1.19 ± 0.21
CAR 1.00 ± 0.10 0.74 ± 0.15 1.51 ± 0.20 1.31 ± 0.24 1.44 ± 0.33 1.26 ± 0.36 1.51 ± 0.20 0.47 ± 0.21
PXR 1.00 ± 0.04 0.81 ± 0.06 1.10 ± 0.16 1.08 ± 0.11 0.85 ± 0.10 0.86 ± 0.10 0.93 ± 0.08 0.60 ± 0.05*
RXR 1.00 ± 0.05 0.76 ± 0.03 0.98 ± 0.06 0.88 ± 0.08 1.08 ± 0.04 0.92 ± 0.06 1.13 ± 0.06 1.06 ± 0.26
AhR 1.00 ± 0.20 0.74 ± 0.07 1.09 ± 0.26 1.04 ± 0.16 0.52 ± 0.03* 1.10 ± 0.17 1.02 ± 0.09 0.68 ± 0.13
ARNT 1.00 ± 0.06 0.86 ± 0.05 0.91 ± 0.02 0.81 ± 0.03 0.69 ± 0.09*** 0.76 ± 0.05** 0.80 ± 0.06 0.74 ± 0.04*
*p < 0.05, **p < 0.01, ***p < 0.001 versus SD-fed animals; #p < 0.05 versus HF-fed animals.
Rats were fed the SD-, inulin-supplemented SD-, HF-, or inulin-supplemented HF diets for 1 week, continued to consume each diet containing fluvastatin (0 or 4
mg/kg/day) for another 2 weeks, and then sacrificed. Relative levels were expressed by taking the control values obtained from SD-diet-fed rats as 1.00. Values
are the means ± S.E. of 4 determinations in each group.
Figure 5 Effects of synthetic inulin and fluvastatin on expression of cytochrome P450 proteins [western blot] in SD or HF diet-fed rats.
Rats (7 weeks of age) were fed the SD, SD + I, HF, or HF + I diet for 1 week, and then administered fluvastatin (0 or 4 mg/kg) with the diet
daily. The rats were sacrificed 14 days after starting the administration of fluvastatin. The microsome proteins (20 μg/lane) were prepared and
subjected to immunoblot analysis.
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Page 8 of 14Figure 6 Effects of synthetic inulin and fluvastatin on expression of cytochrome P450 proteins [levels] in SD or HF diet-fed rats. Rats (7
weeks of age) were fed the SD, SD + I, HF, or HF + I diet for 1 week, and then administered fluvastatin (0 or 4 mg/kg) with the diet daily. The
rats were sacrificed 14 days after starting the administration of fluvastatin. The microsome proteins (20 μg/lane) were prepared and subjected to
immunoblot analysis. The signal intensities were determined with CS analyzer (ATTO Densitograph Software Library). Relative levels are expressed
by taking the control values obtained from SD-fed control animals as 100. Values are the mean ± S.E. of 3 determinations. *p < 0.05, **p < 0.01,
***p < 0.001 versus SD-fed control rats; ##p < 0.01, ###p < 0.001 versus HF-fed control rats.
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Page 9 of 14Figure 7 Effects of synthetic inulin and fluvastatin on hepatic ethoxyresolufin O-deethylase (A) and methoxyresolufin O-deethylase (B)
activities in SD or HF diet-fed rats. Rats (7 weeks of age) were fed the SD, SD + I, HF, or HF + I diet for 1 week, and then administered
fluvastatin (0 or 4 mg/kg) with the diet daily. The rats were sacrificed 14 days after starting the administration of fluvastatin. The microsome
proteins were prepared and analyzed for ethoxyresolufin O-deethylase and methoxyresolufin O-denethylase activities. Values are the mean ± S.E.
of 3 determinations. *p < 0.05, **p < 0.01, ***p < 0.001 versus SD diet-fed control rats; #p < 0.05, ##p < 0.01 versus HF-fed control rats.
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Page 10 of 14translocator (ARNT) mRNA levels were reduced in the
livers of rats fed the HF diet. The synthetic inulin or flu-
vastatin alone ameliorated the reduction in AhR and
ARNT mRNAs, and the co-treatment did not exert
stronger effects than each individual treatment alone,
consistent with the alteration in the expression of
CYP1A1/2 (Table 1 and Figures 5, 6 and 7).
Discussion
Nutritional factors such as starvation, fasting, and a
high-lipid diet, and pathophysiological factors such as
diabetes have been reported to affect liver drug-metabo-
lizing phase I enzymes, leading to the altered hepatic
metabolism of drugs, carcinogens, steroid hormones,
and fatty acids [1-4,11,24-26]. The accumulation of tria-
cylglycerols in the liver, defined as hepatic steatosis, is
proposed to be the first stage of more severe liver dis-
eases such as nonalcoholic steatohepatitis, which shows
histological signs of fibrosis and necroinflammation,
through cirrhosis, terminal liver failure, and hepatocellu-
lar carcinoma [11]. In the previous studies [17,19], we
reported the decrease in portal plasma propionate levels
and severe hepatic steatosis in rats fed the HF diet. Inu-
lin is fermented by colonic microflora, and short-chain
fatty acids such as acetate, propionate and butyrate are
produced and can be absorbed from the colon [14,16].
Propionate is reported to inhibit fatty acid synthesis in
rat hepatocytes [27,28] and the reduction in propionate
levels in portal plasma may be associated with induction
of liver fatty acid synthase. This study demonstrated
that in rats fed the HF diet but not the SD diet for 3
weeks, synthetic inulin (5%) decreased the portal plasma
glucose levels, and suppressed the triacylglycerol accu-
mulation in blood and liver (Figures 1, 2, 3). In addition,
synthetic inulin has been reported to recover the
decreased portal plasma propionate levels (Reference
[17] and Figure 8). Thus, the recovery of portal plasma
propionate levels by synthetic inulin could result in sup-
pression of fatty acid synthesis. These observations were
consistent with the alteration in FAS and CPT1a mRNA
levels (Figures 1, 2, 3, 4). FAS mRNA levels were ele-
vated in the liver of rats fed the HF diet, and dietary
Portal  propionate levels17)
and glucose levels
Synthetic inulin
Statin
Hyperlipidemia
Hepatic steatosis
at an early stage of 
hepatic steatosis
Decrease in hepatic levels of CYP1A1/2 and CYP2E1
High-fat and high-sucrose diet
Xenobiotics-induced adverse effects
Figure 8 Proposed scheme of hyperlipidemia and hepatic steatosis in rats fed the HF diet, xenobiotics-induced adverse effects, and
suppression by synthetic inulin and statin.
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Page 11 of 14inulin suppressed the elevated mRNA levels of fatty acid
synthase, suggesting the suppression of liver de novo
lipogenesis, but the co-treatment with fluvastatin did
not exert stronger effects than each individual treatment
alone. In addition, the mRNA expression of the b-oxida-
tion-related enzyme CPT1a was reduced in the livers of
HF rats, and recovered to nearly normal levels with the
intake of synthetic inulin, indicating the anti-lipogenic
action of synthetic inulin (Figures 1, 2, 3, 4 and 8).
Since the total cholesterol level in the serum was not
suppressed by the synthetic inulin in rats fed the HF
diet (Figure 1), we examined the effects of co-treatment
with synthetic inulin and fluvastatin. Unexpectedly, an
additive or synergistic effect of co-treatment on the sup-
pression of elevated serum and liver total cholesterol
levels was not found, while the suppression of elevated
serum and liver triacylglycerol levels was slightly stron-
ger than that by each individual treatment alone (Fig-
ures 1 and 2). In the previous study [20], we found the
severe adverse effects of fluvastatin (8 mg/kg/day) in
rats fed the HF diet. Preceding the elevation in serum
creatine kinase levels and muscle damage in rats fed the
HF diet containing fluvastatin (8 mg/kg/day), we have
found that serum AST levels were elevated, but the
increase in serum AST levels were not observed in rats
fed the HF diet containing fluvastatin (4 mg/kg/day).
Although fluvastatin at 4 mg/kg/day for 2 weeks did not
change the hepatic levels of its uptake transporter,
organic anion transporter 2, in rats fed the HF diet
(data not shown), undesirable adverse effects of fluvasta-
t i ne v e na tl o wd o s eo f4m g / k g / d a ym a yo c c u rf o r
longer term at the lower rate but those of synthetic inu-
lin were not found for 12 weeks [15,17,19].
The elevated expression of CYP2E1, a microsomal oxi-
dase involved in fatty acid ω-oxidation, as well as
CYP4A, has been shown to be largely responsible for
the pathogenesis of liver disease in patients with nonal-
coholic steatohepatitis and plays a key role in the devel-
opment of liver injury by initiating lipid peroxidation
[3-7]. There was the discrepancy in mRNA and protein
levels of hepatic CYP2E1, while both hepatic CYP2E1
mRNA and protein levels were reduced in rats fed the
HF diet and synthetic inulin tended to recover the levels
(Table 1 and Figure 6D). Rat hepatic CYP2E1 has been
reported to be regulated at two different levels (a tran-
scriptional level to increase CYP2E1 mRNA expression
and a post-transcriptional level to regulate CYP2E1 pro-
tein and activity) [29,30]. In rats fed the HF diet, hepatic
CYP2E1 regulation may occur mainly at the post-tran-
scriptional level. In our previous study [19], we have
demonstrated that the feeding of the HF diet to rats for
8 weeks produces hepatic steatosis, which is associated
with the induction of liver injury by xenobiotics such as
phenobarbital and dexamethasone via induction of
CYP2B and CYP3A expression, but not associated with
liver injury via the alteration of hepatic CYP2E1 and
CYP4As. The present study demonstrated that feeding
the HF diet to rats for 3 weeks reduced CYP2E1 and
CYP1A1/2 mRNA and protein levels, and the improve-
ment in nutritional status in the liver caused by the syn-
thetic inulin alone ameliorated the reduction in the
expression of CYP2E1 and CYP1A1/2, indicating the
reduction to occur in the initial stage in the alteration
of drug-metabolizing enzymes in the fatty liver induced
by a HF diet.
CYP1 enzymes such as CYP1A1, CYP1A2, and
CYP1B1 not only play an important role in the meta-
bolic activation of environmental procarcinogens, but
also metabolize large numbers of clinically important
drugs such as caffeine and theophiline and several
important endogenous substrates such as melatonin,
bilirubin, esteron, and estradiol [31-35]. There have
been many epidemiological studies on the inducibility of
hepatic CYP1A enzymes by diet, and their association
with the metabolism of environmental and dietary carci-
nogens [36-38]. Dietary indolyl glucosinolates and flavo-
noids have been reported to induce CYP1A expression
either through direct interaction with AhR or by aug-
menting the interaction of AhR with xenobiotic
response elements in CYP1A1 and other target genes.
Generally, transcriptional up-regulation of drug-metabo-
lizing phase 1 enzymes by xenobiotics occurs via CAR
(CYP2B induction), PXR (CYP3A induction), AhR
(CYP1A induction), PPARa (CYP4As induction) and
Nrf2 (NADPH-quinone oxidoreductase induction).
CYP1A2 (a major member of the CYP1A subfamily in
rat liver), is partly induced through transactivation
mediated by AhR, which is a ligand-activated transcrip-
tion factor and forms a heterodimer with ARNT. In this
study, we demonstrated that in fatty liver caused by
feeding a HF diet for 3 weeks, the damage from which
occurred prior to nonalcoholic hepatic steatosis,
CYP1A1 and CYP1A2 mRNA and protein expression
and related metabolic activities of ethoxyresorufin O-
deethylase and methoxyresorufin O-demethylase, respec-
tively, were down-regulated (Table 1 and Figures 5, 6
and 7). Since the AhR mRNA level in the liver of rats
fed the HF diet was also reduced, the suppressive effect
of the HF diet on the baseline expression of CYP1A1
and CYP1A2 may be AhR-dependent. Synthetic inulin
ameliorated the change in the expression of CYP1A1
and CYP1A2 in rats fed the HF diet, in association with
a suppression of the development of hepatic steatosis.
Conclusion
This study indicated (1) that changes in the nutritional
status of the liver in rats fed a HF diet may cause
adverse effects due to reduced expression of CYP1A1,
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Page 12 of 14CYP1A2, and CYP2E1, in addition to adverse effects of
lipid-lowering drugs such as fluvastatin and (2) that
intake of dietary inulin alone suppressed the develop-
ment of hepatic steatosis and ameliorated the nutritional
status, followed by a suppression of the reduction in
hepatic expression of drug-metabolizing enzymes such
as CYP1A1, CYP1A2, and CYP2E1, while co-treatment
with statin had slightly additive or synergistic effects.
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